Basal cell carcinoma - Molecular biology and potential new therapies

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 455-463

  Kasper, Maria ^a   Jaks, Viljar ^a,b   Hohl, Daniel ^c   Toftgård, Rune ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BMS 833923; COLECALCIFEROL; CYCLOPAMINE; ERISMODEGIB; FLUOROURACIL; IMIQUIMOD; IPI 926; ITRACONAZOLE; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; PROTEIN INHIBITOR; SMOOTHENED PROTEIN; SMOOTHENED PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; TAK 441; TAZAROTENE; UNCLASSIFIED DRUG; VISMODEGIB;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL STRUCTURE; CRYOTHERAPY; CURETTAGE; DYSGEUSIA; FATIGUE; HAIR LOSS; HUMAN; HYPONATREMIA; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; MUSCLE SPASM; NAUSEA; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TASTE DISORDER; TUMOR CELL;

ANIMALS; CARCINOMA, BASAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HEDGEHOG PROTEINS; HUMANS; MOLECULAR BIOLOGY; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 84856556569     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58779     Document Type: Review

References (99)

1. Jacob A. Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face. Dublin Hospital Rep Commun Med Surg. 1827;4:232-239.
2. Krompecher E. Der drüsenartige Oberflachenepithelkrebs. Carcinoma epi- theliale adenoides. Beitr z path Anat u z adg Path. 1900;28:1-41.
3. Krompecher E. Der Basalzellenkrebs. Jena: Gustav Fischer; 1903.
4. Mallory FB. Recent progress in the microscopic anatomy and differentiation of cancer. JAMA. 1910;55(18):1513-1516.
5. Ten Seldam REJ, Helwig EB. Histological Typing Of Skin Tumours. Geneva, Switzerland: World Health Organization; 1974.
6. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 pt 1):774-778. (Pubitemid 24157120)
7. Jemal A, Siegel R, eds. Cancer Facts and Figures 2011. Atlanta, Georgia, USA: American Cancer Society, Inc.; 2011.
8. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262-2269. (Pubitemid 41697289)
9. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
10. Kerr JF, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol. 1972;107(1):41-44.
11. Shulman O, Laitman Y, Vilan A, Leviav A, Friedman E. Monoclonal origin of anatomically distinct basal cell carcinomas. J Invest Dermatol. 2006;126(3):676-679. (Pubitemid 43255659)
12. Asplund A, Sivertsson A, Backvall H, Ahmadian A, Lundeberg J, Ponten F. Genetic mosaicism in basal cell carcinoma. Exp Dermatol. 2005;14(8):593-600. (Pubitemid 41030926)
13. Jarisch W. Zur Lehre von den Hautgesschwulsten. Arch Dermatol Syphilol (Berl). 1894;28:162-222.
14. White JC. Multiple benign cystic epitheliomas. J Cutan Genitourin Dis. 1894;12:477-484.
15. Howell JB, Caro MR. The basal-cell nevus: its relationship to multiple cutaneous cancers and associated anomalies of development. AMA Arch Derm. 1959;79(1):67-77.
16. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908-912.
17. Evans DG, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327-332.
18. Hahn H, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841-851. (Pubitemid 26192135)
19. Johnson RL, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668-1671. (Pubitemid 26200029)
20. Gailani MR, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78-81. (Pubitemid 26301550)
21. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805(2):181-208.
22. Vabres P, de Prost Y. Bazex-Dupre-Christol syndrome: a possible diagnosis for basal cell carcinomas, coarse sparse hair, and milia. Am J Med Genet. 1993;45(6):786. (Pubitemid 23077338)
23. Michaelsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol. 1981;61(6):497-503. (Pubitemid 12246784)
24. Makitie O, Pukkala E, Teppo L, Kaitila I. Increased incidence of cancer in patients with cartilage-hair hypoplasia. J Pediatr. 1999;134(3):315-318. (Pubitemid 30417640)
25. Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience. 2007;145(4):1388-1396. (Pubitemid 46602743)
26. Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol. 2011;165(1):30-34.
27. Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006;66(4):2081-2088.
28. El-Bahrawy M, El-Masry N, Alison M, Poulsom R, Fallowfield M. Expression of beta-catenin in basal cell carcinoma. Br J Dermatol. 2003;148(5):964-970. (Pubitemid 36750789)
29. Yang SH, et al. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet. 2008;40(9):1130-1135.
30. Kasper M, et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol. 2006;26(16):6283-6298. (Pubitemid 44204544)
31. Schnidar H, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res. 2009;69(4):1284-1292.
32. Wang GY, Wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell. 2011;19(1):114-124.
33. Sneddon JB, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006;103(40):14842-14847. (Pubitemid 44527816)
34. Bogovski P. Tumors of the skin. In: Turusov VS, Mohr U, eds. Pathology of Tumors in Laboratory Animals. Vol 2. Lyon, France: IARC Scientific Publications; 1994:11-12.
35. Grachtchouk V, et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype. Embo J. 2003;22(11):2741-2751. (Pubitemid 36712370)
36. Nilsson M, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A. 2000;97(7):3438-3443. (Pubitemid 30183321)
37. Grachtchouk M, et al. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest. 2011;121(5):1768-1781.
38. Jih DM, et al. Familial basaloid follicular hamartoma: lesional characterization and review of the literature. Am J Dermatopathol. 2003;25(2):130-137. (Pubitemid 36350458)
39. Morris RJ. Keratinocyte stem cells: targets for cutaneous carcinogens. J Clin Invest. 2000;106(1):3-8. (Pubitemid 30437233)
40. Visvader JE. Cells of origin in cancer. Nature. 2011;469(7330):314-322.
41. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 2009;10(3):207-217.
42. Jaks V, Kasper M, Toftgard R. The hair follicle-a stem cell zoo. Exp Cell Res. 2010;316(8):1422-1428.
43. Youssef KK, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12(3):299-305.
44. Jeong J, Mao J, Tenzen T, Kottmann AH, McMahon AP. Hedgehog signaling in the neural crest cells regulates the patterning and growth of facial primordia. Genes Dev. 2004;18(8):937-951. (Pubitemid 38529662)
45. Wong SY, Reiter JF. Wounding mobilizes hair follicle stem cells to form tumors. Proc Natl Acad Sci U S A. 2011;108(10):4093-4098.
46. Ito M, et al. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature. 2007;447(7142):316-320. (Pubitemid 46788832)
47. Ito M, et al. Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med. 2005;11(12):1351-1354. (Pubitemid 41752917)
48. Levy V, Lindon C, Zheng Y, Harfe BD, Morgan BA. Epidermal stem cells arise from the hair follicle after wounding. FASEB J. 2007;21(7):1358-1366. (Pubitemid 46684838)
49. Ridky TW, Khavari PA. The hair follicle bulge stem cell niche resists transformation by the hedgehog pathway. Cell Stem Cell. 2010;6(4):292-294.
50. Kasper M, et al. Wounding enhances epidermal tumorigenesis by recruiting hair follicle keratinocytes. Proc Natl Acad Sci U S A. 2011;108(10):4099-4104.
51. Barnes EA, Kong M, Ollendorff V, Donoghue DJ. Patched1 interacts with cyclin B1 to regulate cell cycle progression. EMBO J. 2001;20(9):2214-2223. (Pubitemid 32410591)
52. Virchow R. Aetiologie der neoplastischen Geschwulste/Pathogenie der neoplastischen Geschwulste. Berlin, Germany: Verlag von August Hirschwald; 1863.
53. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6 pt 1):1118-1126.
54. Grachtchouk M, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet. 2000;24(3):216-217. (Pubitemid 30132187)
55. Brownell I, Guevara E, Bai CB, Loomis CA, Joyner AL. Nerve-derived sonic hedgehog defines a niche for hair follicle stem cells capable of becoming epidermal stem cells. Cell Stem Cell. 2011;8(5):552-565.
56. Jaks V, et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet. 2008;40(11):1291-1299.
57. Oro AE, Higgins K. Hair cycle regulation of Hedgehog signal reception. Dev Biol. 2003;255(2):238-248. (Pubitemid 36331946)
58. Mancuso M, et al. Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation. Cancer Res. 2006;66(13):6606-6614. (Pubitemid 44085616)
59. Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol. 2011;50(6):645-658.
60. So PL, Tang JY, Epstein EH. Novel investigational drugs for basal cell carcinoma. Expert Opin Investig Drugs. 2010;19(9):1099-1112.
61. Binns W, James LF, Shupe JL, Everett G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, veratrum californicum. Am J Vet Res. 1963;24:1164-1175.
62. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998;280(5369):1603-1607. (Pubitemid 28277705)
63. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002;16(21):2743-2748. (Pubitemid 35253140)
64. Athar M, et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 2004;64(20):7545-7552. (Pubitemid 39372099)
65. Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol. 2004;14(2):96-102. (Pubitemid 38510025)
66. Tremblay MR, et al. Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem. 2008;51(21):6646-6649.
67. Von Hoff DD, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
68. LoRusso PM, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
69. Sekulic A, et al. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). Melanoma Research. 2011;21:e9.
70. Tang JY, et al. An investigator-initiated, phase II randomized, double-blind, placebo-controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research. 2011:Abstract nr. LB-1.
71. Rudin CM, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol. 2011;29(1):abstract 3014.
72. Hall JM, Bell ML, Finger TE. Disruption of sonic hedgehog signaling alters growth and patterning of lingual taste papillae. Dev Biol. 2003;255(2):263-277. (Pubitemid 36331948)
73. St-Jacques B, et al. Sonic hedgehog signaling is essential for hair development. Curr Biol. 1998;8(19):1058-1068. (Pubitemid 28451030)
74. Skvara H, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735-1744.
75. Hutchin ME, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005;19(2):214-223. (Pubitemid 40111117)
76. Rudin CM, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173-1178.
77. Yauch RL, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326(5952):572-574.
78. Buonamici S, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70.
79. Dijkgraaf GJ, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71(2):435-444.
80. Kim J, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388-399.
81. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104(20):8455-8460. (Pubitemid 47175509)
82. Hyman JM, et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A. 2009;106(33):14132-14137.
83. Beauchamp EM, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121(1):148-160.
84. Kim J, Lee JJ, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432-13437.
85. Jackson R, Grainge JW. Arsenic and cancer. Can Med Assoc J. 1975;113(5):396-401.
86. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol. 2006;4(8):e232.
87. So PL, et al. Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation. Cancer Res. 2004;64(13):4385-4389.
88. So PL, Fujimoto MA, Epstein EH Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther. 2008;7(5):1275-1284.
89. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276(5313):817- 821. (Pubitemid 27199865)
90. Xie J, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90-92. (Pubitemid 28079221)
91. Aszterbaum M, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med. 1995;5(11):1285-1291. (Pubitemid 29535606)
92. Sheng H, et al. Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. Cancer Res. 2002;62(18):5308-5316. (Pubitemid 35024607)
93. Mancuso M, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res. 2004;64(3):934-941. (Pubitemid 38176895)
94. Svard J, et al. Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell. 2006;10(2):187-197. (Pubitemid 43174952)
95. Siggins SL, et al. The Hedgehog receptor Patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms. Blood. 2009;114(5):995-1004.
96. Mao J, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 2006;66(20):10171-10178. (Pubitemid 44672072)
97. Wong SY, et al. Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis. Nat Med. 2009;15(9):1055-1061.
98. Williams JA, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci U S A. 2003;100(8):4616-4621. (Pubitemid 36457779)
99. Tang T, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res. 2011;17(10):3378-3387.